UNCY — Unicycive Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSmall Cap
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss
Unicycive Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Unicycive Therapeutics Announces Second Quarter 2026 Financial Results And Provides Business Update
Unicycive Therapeutics Q2 net loss narrows on warrant liability change
Unicycive Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
U.S. STOCKS ON THE MOVE-Oklo, Fortune Brands, Air Products
NASDAQ RESUMED AT 07:55 AM
U.S. STOCKS ON THE MOVE-AeroVironment, Oklo
US FDA declines to approve Unicycive's kidney disease drug (updated)
Unicycive plunges after US FDA declines to approve kidney disease drug
Brief: Unicycive Therapeutics Gets Complete Response Letter From FDA On Resubmitted Oxylanthanum Carbonate NDA
US FDA declines to approve Unicycive's drug for dialysis patients
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:00 AM
Brief: Unicycive Therapeutics - Files Base Prospectus To Offer Up To $150 Million In Securities - SEC Filing